UroGen Pharma (URGN) Institutional Ownership

During the previous two years, 106 institutional investors and hedge funds held shares of UroGen Pharma. The most heavily invested institutionals were RTW Investments LP ($40.84M), Cowen AND Company LLC ($35.23M), Adage Capital Partners GP L.L.C. ($31.18M), Menora Mivtachim Holdings LTD. ($26.18M), RA Capital Management L.P. ($20.79M), Toronto Dominion Bank ($18.63M), and Vestal Point Capital LP ($17.36M).Learn more on URGN's institutional investors.

91.29% of UroGen Pharma stock is owned by institutional investors. Learn more on URGN's institutional investor holdings.

Of the 86 institutional investors that purchased UroGen Pharma stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Toronto Dominion Bank ($3.50M), Vestal Point Capital LP ($1.63M), Acorn Capital Advisors LLC ($1.52M), RA Capital Management L.P. ($1.48M), Nantahala Capital Management LLC ($1.37M), Point72 Asset Management L.P. ($1.34M), and RTW Investments LP ($1.15M).

Institutional investors have bought a total of 20,244,672 shares in the last 24 months. This purchase volume represents approximately $255.25M in transactions.

Of the 41 institutional investors that sold UroGen Pharma stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Great Point Partners LLC ($2.67M), Point72 Asset Management L.P. ($2.13M), Stonepine Capital Management LLC ($1.11M), Millennium Management LLC ($853.42K), Adage Capital Partners GP L.L.C. ($807.66K), Harel Insurance Investments & Financial Services Ltd. ($561.85K), and Menora Mivtachim Holdings LTD. ($389.18K).

Institutional investors have sold a total of 9,694,231 shares in the last 24 months. This volume of shares sold represents approximately $112.60M in transactions.